Delivery Order SPE2DB24D9238-SPE2DB26FDQEE
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $10,375.53 by the Defense Logistics Agency on July 18, 2025, for the supply of Nuplazid 34 mg capsules (30-count units). This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, carries no set-aside designation and will be performed at the contractor's Park Ridge, Illinois location. The award represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,373.61 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nuplazid 10 mg tablets (30-count packages). The award, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries a firm fixed-price contract type with no set-aside designation, indicating the vendor competed in unrestricted federal...
- The Defense Logistics Agency awarded a $10,588.89 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count units). The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $10,375.53 for 30 Nuplazid 34 mg capsules by the Defense Logistics Agency's Medical Supply Chain on August 7, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 28, 2025, represents a continuation of pharmaceutical supply services to the Department of Defense healthcare system. The contract carries...
- The Defense Logistics Agency awarded a delivery order valued at $20,751.06 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of NUPLAZID 34 mg capsules (30-count packaging). This firm fixed-price delivery order, issued on October 23, 2025, with an ultimate completion date of November 14, 2025, carries no set-aside designation, indicating the award was made through open competition. The delivery order was...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was issued without a set-aside designation and is being performed at the contractor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is the prime...
- On July 1, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $3,458.51 to DMS Pharmaceutical Group Inc. for the supply of Nuplazid 34 mg capsules (30-count units). This firm fixed-price delivery order is expected to be completed by July 23, 2025, and represents a specific fulfillment under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA under the SPE2DB program. The vendor, a woman-owned small business pharmaceutical wholesaler based in Park...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc. on August 12, 2025, for the supply of Nuplazid 34 mg capsules in quantities of 30. This firm fixed-price delivery order, which carries an ultimate completion date of September 3, 2025, represents a direct procurement with no set-aside designation. The order will be fulfilled from the vendor's location in Park Ridge, Illinois, and supports the pharmaceutical supply needs of Department...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,375.53 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules in 30-count units. The award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, carries a firm fixed-price contract structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on September 29, 2025, for the supply of Nuplazid (pimavanserin) 34 mg capsules in quantities of 30 units. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this delivery order under a firm fixed-price contract with a ceiling value of $10,375.53. The order represents no set-aside designation and carries an ultimate completion date...
- SPE2DB24D9238Indefinite Delivery Contract
- SPE2DB24D9238-SPE2DB26FDQEEDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 30, 2025, for Nuplazid 34 mg capsules (30-count packaging) valued at $10,375.53. This firm fixed-price delivery order, which carries no set-aside designation, represents a specific fulfillment under the company's broader Indefinite Delivery Contract with DLA. The contract will be completed by November 21, 2025, with performance occurring at the contractor's Park Ridge, Illinois facility. This delivery order falls under DMS Pharmaceutical Group's participation in the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. The company's prime vendor contract, valued at $500 million and effective through December 31, 2036, authorizes DLA to issue delivery orders for branded and generic prescription medications, biologics, and other pharmaceutical products. DMS Pharmaceutical Group's demonstrated performance on numerous delivery orders issued throughout October 2025 reflects its established capability as a critical pharmaceutical supplier supporting the federal military medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 10/30/25 |